Revenues were up 35pc to $849m (£532m), partly boosted by an 84pc increase in sales of Replagal, Shire's treatment for Fabry disease, a rare genetic condition affecting the body's ability to break down certain fats.
Replagal sales hit $82m as patients switched to the Shire drug in the wake of shortages of Genzyme's Fabry medicine due to manufacturing problems. Replagal costs an average of $200,000 a year.
via telegraph.co.uk
No comments:
Post a Comment